(19)
(11) EP 4 358 999 A1

(12)

(43) Date of publication:
01.05.2024 Bulletin 2024/18

(21) Application number: 22737464.2

(22) Date of filing: 23.06.2022
(51) International Patent Classification (IPC): 
A61K 39/12(2006.01)
A61K 39/285(2006.01)
C12N 15/00(2006.01)
A61K 39/215(2006.01)
C07K 14/005(2006.01)
A61P 31/14(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 39/12; A61K 39/215; A61K 39/285; C07K 14/005; C12N 2710/20022; C12N 2710/20034; C12N 2710/24143; A61P 31/14
(86) International application number:
PCT/EP2022/067271
(87) International publication number:
WO 2022/269003 (29.12.2022 Gazette 2022/52)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 23.06.2021 EP 21382557
31.12.2021 EP 21383245

(71) Applicant: Consejo Superior De Investigaciones Científicas
28006 Madrid (ES)

(72) Inventors:
  • GARCÍA ARRIAZA, Juan Francisco
    28006 Madrid (ES)
  • ESTEBAN RODRÍGUEZ, Mariano
    28006 Madrid (ES)
  • PÉREZ RAMÍREZ, Patricia
    28006 Madrid (ES)
  • LÁZARO FRÍAS, Adrian
    28006 Madrid (ES)

(74) Representative: Hoffmann Eitle 
Hoffmann Eitle S.L.U. Paseo de la Castellana 140, 3a planta Edificio LIMA
28046 Madrid
28046 Madrid (ES)

   


(54) MVA-BASED VACCINE EXPRESSING A PREFUSION-STABILIZED SARS-COV-2 S PROTEIN